vs
Side-by-side financial comparison of CITIUS ONCOLOGY, INC. (CTOR) and Falcon's Beyond Global, Inc. (FBYD). Click either name above to swap in a different company.
Falcon's Beyond Global, Inc. is the larger business by last-quarter revenue ($6.6M vs $3.9M, roughly 1.7× CITIUS ONCOLOGY, INC.). Falcon's Beyond Global, Inc. runs the higher net margin — -4.5% vs -140.3%, a 135.8% gap on every dollar of revenue.
Citius Oncology, Inc. is a late-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its core pipeline covers treatments addressing unmet medical needs in hematologic malignancies and solid tumors, primarily serving North American and global oncology care markets.
500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.
CTOR vs FBYD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $6.6M |
| Net Profit | $-5.5M | $-296.0K |
| Gross Margin | 80.0% | — |
| Operating Margin | -133.2% | -30.9% |
| Net Margin | -140.3% | -4.5% |
| Revenue YoY | — | 383.5% |
| Net Profit YoY | 16.9% | 97.5% |
| EPS (diluted) | $-0.06 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $6.6M | ||
| Q3 25 | — | $4.1M | ||
| Q2 25 | — | $2.5M | ||
| Q1 25 | — | $1.7M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $1.5M |
| Q4 25 | $-5.5M | $-296.0K | ||
| Q3 25 | — | $-10.4M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $-11.9M | ||
| Q3 24 | — | $39.3M | ||
| Q2 24 | — | $8.0M | ||
| Q1 24 | — | $114.0M |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -133.2% | -30.9% | ||
| Q3 25 | — | -90.9% | ||
| Q2 25 | — | -53.0% | ||
| Q1 25 | — | -371.1% | ||
| Q4 24 | — | -335.6% | ||
| Q3 24 | — | -118.9% | ||
| Q2 24 | — | -195.9% | ||
| Q1 24 | — | -350.5% |
| Q4 25 | -140.3% | -4.5% | ||
| Q3 25 | — | -256.8% | ||
| Q2 25 | — | 985.2% | ||
| Q1 25 | — | -473.8% | ||
| Q4 24 | — | -871.7% | ||
| Q3 24 | — | 1899.5% | ||
| Q2 24 | — | 446.5% | ||
| Q1 24 | — | 7521.4% |
| Q4 25 | $-0.06 | $-0.01 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | — | $0.30 | ||
| Q1 25 | — | $-0.13 | ||
| Q4 24 | — | $-0.25 | ||
| Q3 24 | — | $0.39 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $1.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.3M | $1.9M |
| Total DebtLower is stronger | — | $15.6M |
| Stockholders' EquityBook value | $58.4M | $11.9M |
| Total Assets | $110.0M | $66.7M |
| Debt / EquityLower = less leverage | — | 1.31× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.3M | $1.9M | ||
| Q3 25 | — | $4.3M | ||
| Q2 25 | — | $26.1M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $825.0K | ||
| Q3 24 | — | $828.0K | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $1.1M |
| Q4 25 | — | $15.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | $10.3M | ||
| Q2 24 | — | $15.7M | ||
| Q1 24 | — | $15.1M |
| Q4 25 | $58.4M | $11.9M | ||
| Q3 25 | — | $9.2M | ||
| Q2 25 | — | $414.0K | ||
| Q1 25 | — | $-11.6M | ||
| Q4 24 | — | $-9.0M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-44.7M | ||
| Q1 24 | — | $-61.7M |
| Q4 25 | $110.0M | $66.7M | ||
| Q3 25 | — | $66.8M | ||
| Q2 25 | — | $89.2M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $61.2M | ||
| Q3 24 | — | $66.5M | ||
| Q2 24 | — | $65.9M | ||
| Q1 24 | — | $67.8M |
| Q4 25 | — | 1.31× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.4M | $-4.3M |
| Free Cash FlowOCF − Capex | — | $-4.3M |
| FCF MarginFCF / Revenue | — | -66.0% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.4M | $-4.3M | ||
| Q3 25 | — | $-13.3M | ||
| Q2 25 | — | $-7.9M | ||
| Q1 25 | — | $945.0K | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-3.8M |
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $-13.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $853.0K | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-3.8M |
| Q4 25 | — | -66.0% | ||
| Q3 25 | — | -329.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 49.9% | ||
| Q4 24 | — | -278.7% | ||
| Q3 24 | — | -114.9% | ||
| Q2 24 | — | -145.6% | ||
| Q1 24 | — | -248.8% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.31× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.06× | ||
| Q2 24 | — | -0.33× | ||
| Q1 24 | — | -0.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
